Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 5, 2013, Pages 1120-1129

  Hofer, Beatrice ^a   Dantier, Clothilde ^a   Gebhardt, Klaus ^a   Desarbre, Eric ^a   Schmitt hoffmann, Anne ^a   Page, Malcolm G P ^a  

^a BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

lactamases; MDR; Synergy

Indexed keywords

BAL 30072; CARBAPENEM DERIVATIVE; DORIPENEM; IMIPENEM; MEROPENEM; SIDEROPHORE; UNCLASSIFIED DRUG;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DISK DIFFUSION; DRUG POTENTIATION; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; SEPTICEMIA;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ENTEROBACTERIACEAE; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MONOBACTAMS; PSEUDOMONAS AERUGINOSA; THIAZOLES; THIENAMYCINS;

EID: 84877127230     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks527     Document Type: Article

References (31)

1. Page MGP, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 2010; 54: 2291-302.
2. Mushtaq S, Warner M, Livermore D. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J Antimicrob Chemother 2010; 65: 266-70.
3. Mima T, Kvitko BH, Rholl DA et al. In vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents 2011; 38: 157-9.
4. Russo TA, Page MGP, Beanan JM et al. In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii. J Antimicrob Chemother 2011; 66: 867-73.
5. Higgins PG, Stefanik D, Page MGP et al. In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-nonsusceptible Acinetobacter baumannii. J Antimicrob Chemother 2012; 67: 1167-9.
6. Page MGP. β-Lactamantibiotics. In: Dougherty TJ, Pucci MJ, eds. Antibiotic Discovery and Development. New York: Springer Science+Business Media, LLC, 2012; 79-117.
7. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm!. Trends Mol Med 2012; 18: 263-72.
8. Sidjabat H, Nimmo GR, Walsh TR et al. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi metallo-β-lactamase. Clin Infect Dis 2011; 52: 481-4.
9. Riera E, Cabot G, Mulet X et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother 2011; 66: 2022-7.
10. Pai H, Kim J-W, Kim J et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001; 45: 480-4.
11. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12: 826-36.
12. Pavez M, Neves P, Dropa M et al. Emergence of carbapenem-resistant Escherichia coli producing CMY-2-type AmpC β-lactamase in Brazil. J Med Microbiol 2008; 57: 1590-2.
13. Mammeri H, Nordmann P, Berkani A et al. Contribution of extendedspectrum AmpC (ESAC) β-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol Lett 2008; 282: 238-40.
14. Gröbner S, Linke D, Schütz W et al. Emergence of carbapenem-nonsusceptible extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tü bingen, Germany. J Med Microbiol 2009; 58: 912-22.
15. Page MGP, Dantier C, Desrabre E et al. In vitro and in vivo properties of BAL30376, a β-lactam and dual β-lactamase inhibitor combination with enhanced activity against Gram-negative bacilli that express multiple β-lactamases. Antimicrob Agents Chemother 2011; 55: 1510-9.
16. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. CLSI, Wayne, PA, USA, 2010.
17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests-Tenth Edition: Approved Standard M02-A10. CLSI, Wayne, PA, USA, 2009.
18. Krogsad DJ, Moellering RC. Combinations of antibiotics, mechanism of interaction against bacteria. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Baltimore: The Williams & Wilkins Co., 1980; 299-341.
19. White RL, Burgess DS, Manduru M et al. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 1996; 40: 1914-8.
20. Hebeisen P, Heinze-Krauss I, Angehrn P et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001; 45: 825-36.
21. Odds FC. Synergy, antagonism and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
22. Jones RN, Packer RR. Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins. Antimicrob Agents Chemother 1982; 22: 985-9.
23. Gutmann L, Williamson R, Kitzis MD et al. Synergism and antagonism in double β-lactam antibiotic combinations. Am J Med 1986; 80: 21-9.
24. Pedler SJ, Bint AJ. Combinations of β-lactam antibiotics. BMJ 1984; 288: 1022-3.
25. Ferrara A, Grassi G, Grassi F et al. Bactericidal activity of meropenem and interactions with other antibiotics. J Antimicrob Chemother 1989; 24 Suppl A: 239-50.
26. Stuttman HR, Welch DF, Scribner RK et al. In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients. Antimicrob Agents Chemother 1984; 25: 212-5.
27. Song W, Woo HJ, Kim JS et al. In vitro activity of β-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003; 21: 8-12.
28. Hopefl AW. Overview of synergy with reference to double β-lactam combinations. DICP 1991; 25: 972-7.
29. Suzuki Y, Koguchi M, Fukayama S et al. [Antibacterial activities of combination uses of cefpirome with various antibiotics in vitro against clinically isolated glucose non-fermentative gram-negative rods: part 1. the results against Pseudomonas aeruginosa]. [Article in Japanese, read in translation]. Jpn J Antibiot 1996; 49: 71-82.
30. Oie S, Sawa A, Kamiya A et al. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. J Antimicrob Chemother 1999; 44: 689-91.
31. Page MGP. Resistance mediated by penicillin-binding proteins. In: Bonomo R, Tolmasky ME, eds. Enzyme-Mediated Resistance to Antibiotics: Mechanisms, Dissemination and Prospects for Inhibition. Washington, DC: ASM Press, 2007; 81-99.